Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7599849 | 1.00 | GPR84 (0.61) | GPR84FFAR1FFAR4KDM4EDUSP3 | |
| SCHEMBL12083744 | 1.00 | GPR84 (0.61) | GPR84FFAR1FFAR4KDM4EDUSP3 | |
| SCHEMBL7600154 | 1.00 | GPR84 (0.61) | GPR84FFAR1FFAR4KDM4EDUSP3 | |
| SCHEMBL1269210 | 1.00 | GPR84 (0.61) | GPR84FFAR1FFAR4KDM4EDUSP3 | |
| SCHEMBL7598470 | 1.00 | GPR84 (0.61) | GPR84FFAR1FFAR4KDM4EDUSP3 | |
| SCHEMBL7603423 | 1.00 | GPR84 (0.61) | GPR84FFAR1FFAR4KDM4EDUSP3 | |
| SCHEMBL2310664 | 1.00 | GPR84 (0.61) | GPR84FFAR1FFAR4KDM4EDUSP3 | |
| SCHEMBL7602590 | 1.00 | GPR84 (0.61) | GPR84FFAR1FFAR4KDM4EDUSP3 | |
| SCHEMBL22655388 | 1.00 | GPR84 (0.61) | GPR84FFAR1FFAR4KDM4EDUSP3 | |
| SCHEMBL7599629 | 1.00 | GPR84 (0.61) | GPR84FFAR1FFAR4KDM4EDUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210247400-A1 | ACTIVATION OF PATTERN-TRIGGERED IMMUNITY IN PLANTS BY LIPOOLIGOSACCHARID-SPECIFIC REDUCED ELICITATION (LORE) AND VARIANTS THEREOF | Technische Universität München (DE) | 2021-08-12 | — | — | US | claimed |
| EP-3790387-A1 | ACTIVATION OF PATTERN-TRIGGERED IMMUNITY IN PLANTS BY LIPOOLIGOSACCHARID-SPECIFIC REDUCED ELICITATION (LORE) AND VARIANTS THEREOF | Technische Universität München (DE) | 2021-03-17 | — | — | EP | claimed |
| WO-2019214858-A1 | ACTIVATION OF PATTERN-TRIGGERED IMMUNITY IN PLANTS BY LIPOOLIGOSACCHARID-SPECIFIC REDUCED ELICITATION (LORE) AND VARIANTS THEREOF | Technische Universität München (DE) | 2019-11-14 | — | — | WO | claimed |
| CN-116688981-A | Palladium zinc-bismuth oxide catalyst, preparation method and application thereof in beta-hydroxy ester oxidation | 万华化学集团股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2023135259-A1 | SEMI-INTEGRATED METHOD FOR ENZYME-ASSISTED EXTRACTION AND PURIFICATION OF P-HYDROXYCINNAMIC ACIDS | INSTITUT NATIONAL DES SCIENCES ET INDUSTRIES DU VIVANT ET DE L'ENVIRONNEMENT (AGROPARISTECH) (FR) | 2023-07-20 | — | — | WO | disclosed |
| US-11279733-B2 | Peptide antibiotics | THE UNIVERSITY OF QUEENSLAND (AU) | 2022-03-22 | — | — | US | disclosed |
| US-20210247400-A1 | ACTIVATION OF PATTERN-TRIGGERED IMMUNITY IN PLANTS BY LIPOOLIGOSACCHARID-SPECIFIC REDUCED ELICITATION (LORE) AND VARIANTS THEREOF | Technische Universität München (DE) | 2021-08-12 | — | — | US | disclosed |
| US-20210247400-A1 | ACTIVATION OF PATTERN-TRIGGERED IMMUNITY IN PLANTS BY LIPOOLIGOSACCHARID-SPECIFIC REDUCED ELICITATION (LORE) AND VARIANTS THEREOF | Technische Universität München (DE) | 2021-08-12 | — | — | US | disclosed |
| EP-3790387-A1 | ACTIVATION OF PATTERN-TRIGGERED IMMUNITY IN PLANTS BY LIPOOLIGOSACCHARID-SPECIFIC REDUCED ELICITATION (LORE) AND VARIANTS THEREOF | Technische Universität München (DE) | 2021-03-17 | — | — | EP | disclosed |
| US-20200361994-A1 | PEPTIDE ANTIBIOTICS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-11-19 | — | — | US | disclosed |
| CN-111527100-A | Peptide antibiotics | 昆士兰大学 | 2020-08-11 | — | — | CN | disclosed |
| WO-2012004706-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| CN-101528686-A | Amide compound or salt thereof, and biofilm formation inhibitor, biofilm remover and bactericide each using the amide compound or salt thereof | UNIV TOKYO (JP) | 2009-09-09 | — | — | CN | disclosed |
| EP-2077260-A1 | AMIDE COMPOUND OR SALT THEREOF, AND BIOFILM FORMATION INHIBITOR, BIOFILM REMOVER AND BACTERICIDE EACH USING THE AMIDE COMPOUND OR SALT THEREOF | The University of Tokyo (JP) | 2009-07-08 | — | — | EP | disclosed |
| US-20090068120-A1 | AMIDE COMPOUND OR SALT THEREOF, AND BIOFILM INHIBITOR, BIOFILM REMOVER AND DISINFECTANT CONTAINING THE SAME | OTSUKA CHEMICAL CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| EP-0856510-B1 | Optically active ceramides and process for producing the same | TAKASAGO PERFUMERY CO LTD (JP) | 2002-12-11 | — | — | EP | disclosed |
| US-5998668-A | Optically active compound and process for producing the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0856510-A1 | Optically active ceramides and process for producing the same | Takasago International Corporation (JP) | 1998-08-05 | — | — | EP | disclosed |
| US-5286842-A | Process for producing a biodegradable polymer | MITSUBISHI KASEI CORPORATION (JP) | 1994-02-15 | — | — | US | disclosed |
| EP-0522422-A2 | Process for producing a biodegradable polymer | Mitsubishi Chemical Corporation (JP) | 1993-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068120-A1 | AMIDE COMPOUND OR SALT THEREOF, AND BIOFILM INHIBITOR, BIOFILM REMOVER AND DISINFECTANT CONTAINING THE SAME | Q6ZSR9, F12, H1-0 | GPR84 3926/4885FFAR1 907/4885FFAR4 2201/4885 |
| US-20200361994-A1 | PEPTIDE ANTIBIOTICS | NGLY1, VIP, PEPD | GPR84 2436/4885FFAR1 3474/4885FFAR4 3302/4885 |
| US-11279733-B2 | Peptide antibiotics | NGLY1, VIP, PEPD | GPR84 2436/4885FFAR1 3474/4885FFAR4 3302/4885 |
| US-20210247400-A1 | ACTIVATION OF PATTERN-TRIGGERED IMMUNITY IN PLANTS BY LIPOOLIGOSACCHARID-SPECIFIC REDUCED ELICITATION (LORE) AND VARIANTS THEREOF | PGLS, LIPE, LYPLA2 | GPR84 2281/4885FFAR1 1534/4885FFAR4 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.